Popular on TelAve
- Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 720
- Sales Blueprint Architect Launches, Helping Sales Professionals, Business Owners, and Consultants Close More Business With AI - 702
- CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards - 600
- New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors - 535
- OneVizion Appoints Zebra Technologies CIO Matt Ausman to Board of Directors - 180
- Flexible Plan Investments Announces Retirement of Executive Vice President Renée Toth - 161
- StockResearch AI Initiates Coverage on Apple (AAPL) With New Report Examining Valuation, AI Strategy and Future Growth
- Kentucky's Plane Crash Data Lands Far from the State's Busiest Airports
- DAZN Review 2026: Streaming Price Worth It?
- Experienced eXp Realty Agent Kerri Lawless Guides Buyers and Sellers Through Life's Next Chapters in St. Tammany Parish
Similar on TelAve
- Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
- Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
- Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
- Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
- Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
- Can Government Operate Better Through Innovation?
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
- L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
AlgoDynamix partners with Quant pioneer Dr. Ernie Chan for new Crypto related product developments
TelAve News/10757770
London, Cambridge (UK), Toronto and Niagara-on-the-Lake (Canada) September 8, 2022: AlgoDynamix, the leader in behavioral based price forecasting for financial markets has signed a collaboration agreement with Quant pioneer Dr. Ernie Chan. The agreement covers research, development and productization with a strong initial focus on Crypto. New investment products are expected to be available early Q4 2022.
TelAve -- AlgoDynamix and Dr. Ernie Chan, one of the world's renowned Quant Pioneers, have joined forces to combine their respective expertise to co-launch new investment products with an initial focus on Crypto.
Dr. Ernie Chan, "Crypto is a great asset class with lots of potential, though as we have seen in the past few months it can be very challenging!". Dr. Chan continues: "I am delighted to be partnering with the AlgoDynamix team to make the most of this newer asset class, we will announce further updates soon, including new investment product launches in early Q4 this year"
Throughout the last three decades Dr. Chan has transformed the financial services industry using his mathematical rigor. This already started back in the days of his IBM research and continued with ongoing research at the bulge bracket investment banks as well as the smaller more efficient hedge funds. His latest venture includes advanced predictive analytics and partnerships that maximize his decades of multi-asset trading, tail risk management, portfolio construction and flawless trade execution.
More on TelAve News
Tarun Khanna, President AlgoDynamix North America: "We are absolutely delighted to be working with Dr. Ernie Chan on groundbreaking new Crypto investment products. Our initial discussions with Dr. Chan made it clear that there was definitely an opportunity to work together and to combine the best of all worlds."
Updates and further announcements will be available throughout Q4, please do join AlgoDynamix mailing list for latest updates.
Disclaimers
Press releases and website disclaimers
About AlgoDynamix
Home - AlgoDynamix (UK) overview @ Amadeus Capital Partners
About Dr. Ernest P. Chan
Home - E.P. Chan & Associates (epchan.com)
Dr. Ernie Chan, "Crypto is a great asset class with lots of potential, though as we have seen in the past few months it can be very challenging!". Dr. Chan continues: "I am delighted to be partnering with the AlgoDynamix team to make the most of this newer asset class, we will announce further updates soon, including new investment product launches in early Q4 this year"
Throughout the last three decades Dr. Chan has transformed the financial services industry using his mathematical rigor. This already started back in the days of his IBM research and continued with ongoing research at the bulge bracket investment banks as well as the smaller more efficient hedge funds. His latest venture includes advanced predictive analytics and partnerships that maximize his decades of multi-asset trading, tail risk management, portfolio construction and flawless trade execution.
More on TelAve News
- Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
- Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
- Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
- Can Government Operate Better Through Innovation?
- Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
Tarun Khanna, President AlgoDynamix North America: "We are absolutely delighted to be working with Dr. Ernie Chan on groundbreaking new Crypto investment products. Our initial discussions with Dr. Chan made it clear that there was definitely an opportunity to work together and to combine the best of all worlds."
Updates and further announcements will be available throughout Q4, please do join AlgoDynamix mailing list for latest updates.
Disclaimers
Press releases and website disclaimers
About AlgoDynamix
Home - AlgoDynamix (UK) overview @ Amadeus Capital Partners
About Dr. Ernest P. Chan
Home - E.P. Chan & Associates (epchan.com)
Source: AlgoDynamix (UK) Ltd.
Filed Under: Technology
0 Comments
Latest on TelAve News
- L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
- Mom Era, Still That Girl: Family Art Tees 25% Off
- Fashion vs. Fascism - Because Democracy Should Always Be In Style
- Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast
- Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
- International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
- Boston Industrial Solutions Introduces Personalized Printing Training
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
- FOCUS Names Mark Phillips Senior Vice President of Business Development
- Notaron Expands Online Notarization Access Following Wisconsin Approval
- Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
- The Social Capital Revolution Comes to Phoenix!
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
- FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
- Bettingbladet releases H1 2026 report on the Swedish online gambling market
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP